Positive Results in Alzheimer’s Trial
After many years of clinical trial failures in Alzheimer’s disease, pharma is sees some positive results – although caution is recommended
Stephanie Sutton |
Eisai and Biogen’s experimental BAN2401 drug – a humanized mAb designed as an anti beta-amyloid therapy) hit targets in a Phase II trial involving patients with early Alzheimer’s disease, slowing clinical decline and reducing amyloid beta accumulated in the brain measured using amyloid positron emission tomography (1). The drug was tested at various doses, with all showing a reduction in amyloid plaques, but a slowing of cognitive decline was only seen with the highest dose (10 mg/kg biweekly) – patients on this dose declined 30 percent slower compared with placebo.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine